Skip to main content
. Author manuscript; available in PMC: 2016 Jan 1.
Published in final edited form as: Cancer Chemother Pharmacol. 2014 Nov 21;75(1):161–171. doi: 10.1007/s00280-014-2626-2

Fig. 6.

Fig. 6

Comparison of the pharmacokinetic profiles of sorafenib and t-CUPM. PK study was performed by cassette oral administration at a dose of 1 mg/kg (n = 3) in mice. R2 is the square of the correlation coefficient between predict and observed value; Tmax the time of maximum concentration, Cmax the maximum blood concentration, t1/2 half-life, and AUCt area under the concentration–time curve to terminal time. *P value < 0.05 as compared to the AUCt of sorafenib